Nanjing Cellnuo Biotechnology

Nanjing Cellnuo Biotechnology is a clinical-stage biopharmaceutical company focused on developing next-generation cell therapies for solid tumors. The company utilizes its proprietary technology to engineer CAR-T and TCR-T cells capable of overcoming the immunosuppressive tumor microenvironment, a major hurdle in treating solid malignancies. Its lead program, CN-001, targets Glypican-3 (GPC3) and is currently in Phase 1 clinical trials for advanced hepatocellular carcinoma. Additionally, the company is advancing a pipeline of candidates targeting Claudin 18.2 and Mesothelin for various gastrointestinal and other solid cancers. Nanjing Cellnuo aims to provide curative options for cancer patients through innovative cellular engineering and precision oncology.